Put Options

8 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q1 2022

May 17, 2022

SELL
$21.19 - $40.01 $23,309 - $44,011
-1,100 Reduced 0.95%
114,700 $2.95 Million
Q4 2021

Feb 15, 2022

BUY
$30.97 - $54.03 $2.36 Million - $4.11 Million
76,100 Added 191.69%
115,800 $4.85 Million
Q3 2021

Nov 16, 2021

BUY
$34.9 - $54.54 $279,200 - $436,320
8,000 Added 25.24%
39,700 $1.73 Million
Q2 2021

Aug 16, 2021

SELL
$38.75 - $51.0 $561,875 - $739,500
-14,500 Reduced 31.39%
31,700 $1.5 Million
Q1 2021

May 18, 2021

SELL
$26.34 - $83.07 $147,504 - $465,191
-5,600 Reduced 10.81%
46,200 $2.37 Million
Q4 2020

Feb 17, 2021

BUY
$25.51 - $43.38 $94,387 - $160,506
3,700 Added 7.69%
51,800 $1.39 Million
Q3 2020

Nov 17, 2020

SELL
$28.28 - $53.6 $342,188 - $648,560
-12,100 Reduced 20.1%
48,100 $1.65 Million
Q2 2020

Aug 17, 2020

BUY
$27.89 - $47.86 $1.68 Million - $2.88 Million
60,200 New
60,200 $2.47 Million

Others Institutions Holding VIR

About Vir Biotechnology, Inc.


  • Ticker VIR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 132,638,000
  • Market Cap $922M
  • Description
  • Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...
More about VIR
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.